# Delivery Order #75N91026F00001

Clinical-Grade LFA-9 Manufacturing Delivery Order to MRIGlobal

**Buyer:** National Institutes of Health

**Award Amount:** $337,762.00
**Ceiling:** $337,762.00

**Awarded:** September 21, 2026
**Period of Performance:** Sep 21, 2026 - Sep 20, 2027

**Identifier:** 75N91026F00001
**NAICS:** 541690

This award represents a delivery order contract under an existing Indefinite Delivery Indefinite Quantity (IDIQ) agreement with MRIGlobal, a health research organization specializing in chemopreventive agent repository and chemistry support services. The contract involves the manufacturing of clinical-grade LFA-9, a specialized chemical agent critical for cancer prevention studies, highlighting its importance in advancing medical research and public health. The work focuses on producing high-quality chemical compounds to support ongoing cancer prevention initiatives. The delivery order follows competitive procurement procedures linked to the IDIQ contract and extends MRIGlobal's proven expertise under this umbrella agreement. The contract period spans one year, emphasizing a targeted and timely production effort. The contract contributes significantly to the National Institutes of Health's Division of Cancer Prevention goals by ensuring a reliable supply of essential research-grade reagents.

### Description

MANUFACTURE OF CLINICAL-GRADE LFA-9

[View original record](https://www.usaspending.gov/award/CONT_AWD_75N91026F00001_7529_75N91023D00010_7529)
